medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2014, Number 3

<< Back Next >>

VacciMonitor 2014; 23 (3)

Advances in the characterization of a proteol iposome derived from Mycobacterium bovis BCG as vaccine candidate against tuberculosis

Alvarez-Cabrera N, Fernández-Castillo S, Serpa-Almaguer D, Serrano-Hernández D, Zayas-Vignier C, Cabrera-Arias RA, Acevedo-Grogues R, Peña-Sánchez V, Mohd-Nor N, Sarmiento-García-San Miguel ME, Acosta-Domínguez A, Pérez-Quiñoy JL

Language: Spanish
References: 24
Page: 110-116
PDF size: 284.73 Kb.


ABSTRACT

Despite efforts to eradicate tuberculosis (TB) worldwide, this remains a serious health problem. The Bacillus Calmette-Guerin (BCG), the only available vaccine against TB, has variable efficacy and though protects against severe forms of the disease in childhood, has a questionable role in the protection against pulmonary tuberculosis in adults. In recent years, new TB vaccine candidates are being developed using multiple vaccine strategies. Taking into account the antigenic similarity of M. bovis BCG and M. tuberculosis, and the history of the use of proteoliposomes in vaccine formulations, we aimed to study the potentialities of a proteoliposome derived from M. bovis BCG (PLBCG) as a potential vaccine candidate against TB. The results demonstrate that a PLBCG was obtained, which was observed by different techniques and that is composed of nanoparticulate vesicles. Additionally, analysis by SDSPAGE followed by Coomassie stained showed the presence of several protein bands on PLBCG whose molecular size may correspond with that reported for M. bovis BCG protein having homology to M. tuberculosis.


REFERENCES

  1. World Health Organization. Global Tuberculosis Report. Geneva: WHO;2013.

  2. Frick M. The TB vaccines pipeline: where are we going, where have we been? In: Benzacar A. The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Immunebased and Gene Therapies and Research toward the Cure. New York: Base and Treatment Action Group;2013.p.263-83.

  3. Pérez JL, Acevedo R, Callicó A, Fernández Y, Cedré B, Año G, et al. A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae 01 in Balb/c mice. Vaccine 2009;27:205-12.

  4. Sotolongo F, Campa C, Casanueva V, Fajardo EM, Cuevas IE, González N. Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application. MEDICC Review 2008;9(1):16-22.

  5. Rodriguez L, Tirado Y, Reyes F, Puig A, Kadir R, Borrero R, et al. Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice. Vaccine 2011;29:6236-41.

  6. Reyes F, Tirado Y, Puig A, Borrero R, Reyes G, Fernandez S, et al. Immunogenicity and cross-reactivity against Mycobacterium tuberculosis of proteoliposomes derived from Mycobacterium bovis BCG. BMC Immunol 2013;14(Suppl 1):S7.

  7. Garnier KE, Camus JC, Medina N, Mansoor H, Pryor M, Duthoy SG, et al. The complete genome sequence of Mycobacterium bovis. PNAS 2003;100(13):7877-82.

  8. Lowry O, Rosebrough N, Farr A, Randall R. A protein measurement with the folin-phenol reagent. Biol Chem 1951;193:265-75.

  9. Laemmli NK. Cleareange of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.

  10. Fernández S, Fajardo EM, Mandiarote A, Año G, Padrón MA, Acosta M, et al. A proteoliposome formulation derived from Bordetella pertussis induces protection in two murine challenge models. BMC Immunology 2013;14(Suppl 1):S8.

  11. Woeste S, Demchick P. New version of the negative stain. Appl Environ Microbio 1991;57(6):1858-9.

  12. Seki IH, Fujita I, Yano I, Yamamoto S, Koyama A. Whole genome sequence analysis of Mycobacterium bovis bacillus Calmette–Guerin (BCG) Tokyo 172: A comparative study of BCG vaccine substrains. Vaccine 2009;27:1710-6.

  13. Horth G, Horwitz M, Tabatadize D, Zameenick P. Targeting the Mycobacterium tuberculosis 30/32 kDa mycolil transferase complex as therapeutic strategy against tuberculosis. Proof of principle by using antisense technology. PNAS 2002;99:15614-9.

  14. Kremer L, Bouler A, Estoquier J, Content J, Capron A, Locht C. Analysis of the Mycobacterium tuberculosis 85 kDa antigen promoter region. J Bacteriology 1995;177(3):642-53.

  15. Brun P, Zumbo A, Castagliuolo I, Delogu G, Manfrin F, Sali M, et al. Intranasal delivery of DNA encoding antigens of Mycobacterium tuberculosis by non-pathogenic invasive Escherichia coli. Vaccine 2008;26:1934-41.

  16. Dhar N, Rao V, Tyagi A. Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis. Med Microbiol Immunol 2004;193:19-25.

  17. Malin A, Huygen K, Content J, Mackett M, Brandt L, Andersen P, et al. Vaccinia expression of Mycobacterium tuberculosissecreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85. Microbes Infect Immun 2000;2:1677-85.

  18. Reyes F, Tirado Y, Puig A, Borrero R, Reyes G, Fernandez S, et al. Immunogenicity and cross-reactivity against Mycobacterium tuberculosis of proteoliposomes derived from Mycobacterium bovis BCG. BMC Immunol 2013;14(Suppl 1):S7.

  19. Kelkar D, Kumar D, Kumar P, Balakushnan L, Mulliusamy B, Yadav A. Proteogenomic analysis of M. tuberculosis by high resolution mass espectometry. Mol Cell Proteomic 2011;10(12). Disponible en: doi: 10.1074/mcp.M111.011445.

  20. Tasneem S, Islam N, Ali R. Cross reactivity of SLE autoantibodies with 70 kDa heat shock protein of M. tuberculosis. Microbiology Inmunol 2001;45(12):841-6.

  21. Martínez I, Muñoz Y, Iglesias N, Fajardo E, Balboa J, Riveron L, et al. Aportes Analíticos al Control de Calidad de la Vacuna Cubana VA-MENGOC BC® y de una Nueva Vacuna Antitifoidea. Acta Farm Bonaerense 2006;25(2):231-8.

  22. Seymour R. History of Polimer Science and technology. Gene therapy 1996;3:269-73.

  23. Acevedo, R. Obtención y Caracterización de una nueva estructura coclear con capacidad adyuvante derivada del proteoliposoma Vibrio cholerae 01. [Tesis Doctoral]. La Habana: BVS; 2011. Disponible en: http://tesis.repo.sld.cu/view/autores/Acevedo_Grogue s=3AReinaldo=3A=3A.html

  24. Lastre M, Pérez O, Labrada A, Pérez DA, Bracho GR, del Campo JM, et al inventors. Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas. OCPI Patente No. 22983. 2004 Nov 20.




2020     |     www.medigraphic.com